Stockscreener 앱 받기
12.08
0.84%
-0.1042
전일 마감가:
$12.18
열려 있는:
$12.19
하루 거래량:
250.45K
Relative Volume:
0.20
시가총액:
$610.32M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-3.2726
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
-6.59%
1개월 성능:
-10.27%
6개월 성능:
+8.27%
1년 성능:
+6.04%
1일 변동 폭
$11.98
$12.43
1주일 범위
$11.54
$12.74
52주 변동 폭
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
12.08 | 615.37M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.99 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
608.50 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.88 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
768.60 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
343.08 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Is KalVista Pharmaceuticals Inc. (4XC1) stock included in top ETFsMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Is KalVista Pharmaceuticals Inc. forming a bottoming base2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
What drives KalVista Pharmaceuticals Inc 4XC1 stock priceEarnings Per Share Trends & Affordable Trading Strategies - earlytimes.in
Can KalVista Pharmaceuticals Inc. stock sustain free cash flow growthJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
KalVista Pharmaceuticals Completes Convertible Notes Sale - TipRanks
Custom strategy builders for tracking KalVista Pharmaceuticals Inc.2025 Dividend Review & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-09-28 22:29:02 - earlytimes.in
With HAE Drug EKTERLY Off To A Strong Start, Is Now The Time To Keep An Eye On KalVista Stock? - Nasdaq
KalVista prices upsized offering of $125M of 3.250% notes due 2031 - MSN
KalVista to offer $110M in convertible notes; shares down 10% - MSN
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 6.9%What's Next? - MarketBeat
Ekterly approved as on-demand therapy for HAE in EU, Switzerland - Angioedema News
KalVista Prices Upsized Offering of $125.0 Million of 3.250 Convertible Senior Notes Due 2031 - MarketScreener
KalVista Pharma falls after $125 mln convertible debt sale - TradingView
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 - Business Wire
KalVista Pharmaceuticals Prices $125 Million Notes Offering - MarketScreener
KalVista plans to offer $110 million in convertible notes By Investing.com - Investing.com Canada
KalVista prices $125 million convertible senior notes offering - Investing.com
KalVista prices $125 million convertible senior notes offering By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals stock falls after convertible notes offering By Investing.com - Investing.com Canada
Kalvista Pharmaceuticals announces proposed offering of $110.0 million of convertible senior notes - MarketScreener
KalVista plans to offer $110 million in convertible notes - Investing.com
Kalvista Pharmaceuticals stock falls after convertible notes offering - Investing.com India
KalVista (KALV) Plans $110M Convertible Senior Notes Offering - GuruFocus
KalVista Pharmaceuticals Proposes Private Offering of $110 Million of Convertible Notes; Shares Fall After Hours - MarketScreener
KalVista Pharma falls after announcing $110 mln convertible debt offering - TradingView
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes - The Joplin Globe
KalVista Pharmaceuticals Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Rhumbline Advisers - Defense World
Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
KalVista’s Regulatory Victory Meets Market Skepticism - AD HOC NEWS
KalVista’s Ekterly approved in EU and Switzerland - The Pharma Letter
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema - BioSpace
Decliners Report: What analysts say about KalVista Pharmaceuticals Inc stockJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - خودرو بانک
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
Analyzing KalVista Pharmaceuticals Inc. with risk reward ratio charts2025 Investor Takeaways & Daily Price Action Insights - newser.com
Hereditary Angioedema Pipeline Drugs Report 2025 - openPR.com
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year - Stocktwits
KalVista’s oral HAE treatment Ekterly receives EU and Swiss approval - Investing.com India
Earnings Miss: Can KalVista Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Market Mood & Low Risk Profit Maximizing Plans - khodrobank.com
KalVista (KALV) Secures EU Approval for Hereditary Angioedema Tr - GuruFocus
KalVista’s oral HAE treatment Ekterly receives EU and Swiss approval By Investing.com - Investing.com Nigeria
Gold miners, Perpetua Resources, KalVista Pharmaceuticals - TradingView
KalVista (KALV) Gains European and Swiss Approval for Ekterly - GuruFocus
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY - Business Wire
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
자본화:
|
볼륨(24시간):